GT
NTLA icon

Glenmede Trust’s Intellia Therapeutics NTLA Stock Holding History

Glenmede Trust’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,406
Closed -$246K – 1324
2022
Q3 		$246K Buy
+4,406
New +$273K ﹤0.01% 1025
2022
Q2 		– Sell
-5,375
Closed -$390K – 1349
2022
Q1 		$390K Sell
5,375
-51
-0.9% -$4.32K ﹤0.01% 970
2021
Q4 		$641K Sell
5,426
-518
-9% -$64.9K ﹤0.01% 856
2021
Q3 		$797K Sell
5,944
-452
-7% -$68.4K ﹤0.01% 764
2021
Q2 		$1.03M Sell
6,396
-2,189
-25% -$170K 0.01% 697
2021
Q1 		$688K Sell
8,585
-283
-3% -$19K ﹤0.01% 754
2020
Q4 		$481K Hold
8,868
– – ﹤0.01% 851
2020
Q3 		$175K Sell
8,868
-3,078
-26% -$64.2K ﹤0.01% 1047
2020
Q2 		$249K Buy
11,946
+4,399
+58% +$74.7K ﹤0.01% 958
2020
Q1 		$109K Hold
7,547
– – ﹤0.01% 1392
2019
Q4 		$109K Buy
7,547
+4,200
+125% +$58.4K ﹤0.01% 1392
2019
Q3 		$43 Buy
3,347
+597
+22% +$9.52K ﹤0.01% 1727
2019
Q2 		$45 Hold
2,750
– – ﹤0.01% 1723
2019
Q1 		$46 Hold
2,750
– – ﹤0.01% 1726
2018
Q4 		$37 Buy
+2,750
New +$51.1K ﹤0.01% 1718
2018
Q3 		– Sell
-3,100
Closed -$85K – 1693
2018
Q2 		$85K Buy
+3,100
New +$75.1K ﹤0.01% 1300

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Glenmede Trust's NTLA Position: Q4 2022 in Review

Glenmede Trust sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 4,406 shares — an estimated $246K sold.

Glenmede Trust first reported a position in NTLA in Q2 2018 and held it in 16 quarters. The position peaked at $1.03M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

  • Glenmede Trust reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Glenmede Trust sold 4,406 Intellia Therapeutics shares in Q4 2022, an estimated $246K.
  • Glenmede Trust first reported a position in Intellia Therapeutics in Q2 2018 and held it in 16 quarters.
  • Glenmede Trust's Intellia Therapeutics position peaked at $1.03M in Q2 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Glenmede Trust's 13F filing for Q4 2022, filed 14 Feb 2023.